News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

GENpathway Inc. Signs Worldwide Agreement With Affymetrix (Santa Clara, California) (AFFX) To Provide ChIP-On-Chip Assay Services For New GeneChip(R) Tiling Array Systems

7/26/2006 5:34:29 PM

SAN DIEGO, July 26 /PRNewswire/ -- Genpathway announced today that it has entered into a worldwide services agreement with Affymetrix, Inc. (Nasdaq: AFFX - News) whereby Genpathway will provide ChIP (chromatin immunoprecipitation)-on-Chip assays, services, and analysis to pharmaceutical, biotechnology, and academic/institutional researchers using the new Affymetrix GeneChipĀ® Tiling Array Systems.

Affymetrix' recently launched GeneChip Tiling Array product line enables researchers to identify specific DNA sequences, including those involved in DNA-protein interactions, at the whole-genome scale. When applied to ChIP-on- Chip, these new assays enable comprehensive discovery of binding sites for transcription factors and co-regulators and the genes they regulate, as well as genes undergoing active transcription, across entire genomes. Combining Genpathway's assays and expertise in chromatin immunoprecipitation with the Affymetrix GeneChip Tiling Arrays provides pharmaceutical, biotechnology, and academic/institutional researchers working on a wide range of genomes a complete ChIP-on-Chip discovery solution.

"With this agreement, researchers in any laboratory can have instant access to ChIP-on-Chip data generated by Affymetrix GeneChip Tiling Arrays. This information will enable them to look beyond the known protein-coding gene sequences to thoroughly study gene structure, function, and regulation," said Lianne McLean, senior director, Gene Expression Marketing, Affymetrix. We are confident with Genpathway's ability to offer the level of performance and reproducibility our users require."

"Interest in and demand for ChIP-on-Chip assays is expanding rapidly," said Benjamin Monderer, PhD, CEO of Genpathway. "We are delighted to complete this agreement with Affymetrix and look forward to providing an immediate total solution to the current challenges presented by complicated chromatin immunoprecipitation methods when applied to tiling arrays."

Genpathway offers the following ChIP assay services using the new Affymetrix tiling arrays:

* TranscriptionPath ChIP-on-Chip/Tiling(TM) * FactorPath ChIP-on-Chip/Tiling(TM) * FactorPath ChIP-on-Chip/Promoter(TM)

About TranscriptionPath(TM) and FactorPath(TM)

Genpathway's transcription-based assays include TranscriptionPath(TM), which directly analyzes the process of transcription; and FactorPath(TM), which directly analyzes how genes are regulated by transcription factors and co-regulating factors. These two types of direct DNA-based assays may be used separately or in combination to correlate changes in gene regulation and transcription. Genpathway offers both types of assay as a service with four modes of analysis:

* ChIP Query Assays: Quantitative and highly reproducible Q-PCR-based assays * ChIP Discovery Assays: Assays to find new binding sites and transcribed regions across the genome * ChIP Expanded Discovery Assays: Comprehensive genome-wide discovery assays for factor binding sites and genes * ChIP-on-Chip Assays: Genome-wide assays combining chromatin immunoprecipitation and Affymetrix GeneChipĀ® Tiling Arrays


Genpathway, Inc. is a leading provider of ChIP (chromatin immunoprecipitation) technologies and services that identify and analyze gene expression mechanisms and their biological pathways to drive discovery and testing of novel pharmaceuticals, biomarkers, and diagnostic tests. Genpathway's assays directly analyze gene transcription, gene regulation by transcription factors and co-regulators, and the corresponding genetic pathways. These assays, provided as a service by Genpathway, are in use by the top pharmaceutical companies as well as biotechnology, diagnostics, and agriculture companies; and by academic, government, and nonprofit research institutes worldwide.


Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChipĀ® technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been installed around the world and nearly 4,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 1,000 employees worldwide. For more information about Affymetrix, please visit the company's website at

Contact: Mary Moynihan M2Friend Biocommunications 802-951-9600

Source: Genpathway, Inc.

Read at

comments powered by Disqus